Dr. Silbermann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3181 SW Sam Jackson Park Rd., OC14HO
Portland, OR 97239- Is this information wrong?
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2008 - 2011
University of RochesterResidency, Internal Medicine, 2004 - 2007
The Warren Alpert Medical School of Brown UniversityClass of 2004
Certifications & Licensure
OR State Medical License 2017 - 2025
WA State Medical License 2016 - 2024
ID State Medical License 2021 - 2024
IN State Medical License 2012 - 2017
PA State Medical License 2008 - 2012
NY State Medical License 2007 - 2008- American Board of Internal Medicine Hematology
Clinical Trials
- A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma Start of enrollment: 2014 Oct 01
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide Start of enrollment: 2023 Jan 18
Roles: Contact
- Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma Start of enrollment: 2022 Jun 14
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach, Timothy M Schmidt, Douglas W Sborov, Eva Medvedova, Brandi Reeves, Binod Dha...> ;Blood Cancer Journal. 2024 Apr 22
- Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethas...Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J Costa, Larry D Anderson Jr, Nitya Nathwa...> ;American Journal of Hematology. 2024 Apr 15
- 4 citationsMinimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.Costa, L., Chhabra, S., Medvedova, E., Dholaria, B., Schmidt, T., Godby, K., Silbermann, R., Dhakal, B., Bal, S., Giri, S., D'Souza, A., Hall, A., Hardwick, P., Omel, ...> ;The Lancet. Haematology. 2023 Nov 1
- Join now to see all
Abstracts/Posters
- Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)Rebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...Rebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple MyelomaRebecca W. Silbermann, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Daratumumab Regimen Confers Health-Related Quality of Life Benefit in Multiple MyelomaDecember 11th, 2022- Multiple Myeloma: Choosing Your PathDecember 18th, 2020
OncLive® Presents Seven State of the Science Summit™ Meetings in MarchFebruary 26th, 2020- Join now to see all
Hospital Affiliations
OHSU HospitalPortland, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
